To assess the plasma concentration of tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer harboring ALK rearrangement, EGFR or BRAF V600E mutation
Latest Information Update: 17 Oct 2019
At a glance
- Drugs Crizotinib (Primary) ; Dabrafenib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Osimertinib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
Most Recent Events
- 17 Oct 2019 New trial record
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer